| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/02/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 10/14/2021 | 837.5% | Maxim Group | → $18 | Initiates Coverage On | → Buy |
| 01/05/2021 | 785.42% | HC Wainwright & Co. | → $17 | Initiates Coverage On | → Buy |
Kazia Therapeutics Questions & Answers
The latest price target for Kazia Therapeutics (NASDAQ: KZIA) was reported by HC Wainwright & Co. on August 2, 2022. The analyst firm set a price target for $0.00 expecting KZIA to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for Kazia Therapeutics (NASDAQ: KZIA) was provided by HC Wainwright & Co., and Kazia Therapeutics downgraded their neutral rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kazia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kazia Therapeutics was filed on August 2, 2022 so you should expect the next rating to be made available sometime around August 2, 2023.
While ratings are subjective and will change, the latest Kazia Therapeutics (KZIA) rating was a downgraded with a price target of $0.00 to $0.00. The current price Kazia Therapeutics (KZIA) is trading at is $1.92, which is out of the analyst's predicted range.
